Research and Markets (http://www.researchandmarkets.com/research/6n47fn/bacterial)
has announced the addition of Global Markets Direct's new report
"Bacterial Infections - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Bacterial Infections - Pipeline Review, H2
2012', provides an overview of the indication's therapeutic pipeline.
This report provides information on the therapeutic development for
Bacterial Infections, complete with latest updates, and special features
on late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Bacterial Infections.
Bacterial Infections - Pipeline Review, Half Year is built using data
and information sourced from Global Markets Direct's proprietary
databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites
and industry-specific third party sources, put together by Global
Markets Direc's team.
- A snapshot of the global therapeutic scenario for Bacterial Infections.
- A review of the Bacterial Infections products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging
from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
- Coverage of the Bacterial Infections pipeline on the basis of route of
administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Some of the Companies Mentioned:
Shionogi & Co., Ltd.
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Taisho Pharmaceutical Co., Ltd.
Dr. Reddy's Laboratories Limited
Meiji Holdings Co., Ltd.
Nippon Shinyaku Co., Ltd.
Aquapharm Biodiscovery Limited
Amura Holdings Ltd.
Aridis Pharmaceuticals LLC
AiCuris GmbH & Co. KG
Destiny Pharma Ltd.
KYORIN Pharmaceutical Co., Ltd.
Trius Therapeutics, Inc.
SelectX Pharmaceuticals, Inc.
Spider Biotech S.r.l.
Durata Therapeutics Inc.
Cantab Biopharmaceuticals Limited
For more information visit http://www.researchandmarkets.com/research/6n47fn/bacterial
Source: Global Markets Direct
[ Back To NFVZone's Homepage ]